SCHEMBL1759809

SCHEMBL1759809

NC(O)Cc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
FPR2 P25090 2/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
NPC1 O15118 4/20 0.50
RAB9A P51151 3/20 0.50
HTT P42858 3/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 2/20 0.50
NLRP3 Q96P20 2/20 0.50
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NLRP1 Q9C000 1/20 0.50
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19234900 0.84 SLC7A5 (0.54) CNR1HDAC1HDAC6FPR2MEN1
SCHEMBL19234894 0.84 SLC7A5 (0.54) CNR1HDAC1HDAC6FPR2MEN1
SCHEMBL10763436 0.82 SLC6A4 (0.67) SLC6A2
SCHEMBL20715480 0.82 FPR2 (0.60) CNR1HDAC1HDAC6FPR2MEN1
SCHEMBL4167790 0.80 CNR1 (0.60) CNR1HDAC1HDAC6MEN1KMT2A
SCHEMBL4741253 0.78 MEN1 (0.76) CNR1HDAC1HDAC6MEN1KMT2A
SCHEMBL11048619 0.78 MEN1 (0.76) CNR1HDAC1HDAC6MEN1KMT2A
SCHEMBL4121749 0.76 RAB9A (0.67) CNR1HDAC1HDAC6MEN1KMT2A
SCHEMBL20397674 0.75 ROCK2 (0.59) CNR1HDAC1HDAC6FPR2NPC1
SCHEMBL1759807 0.74 CNR1 (0.57) CNR1HDAC1HDAC6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499121-A1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. F. Hoffmann-La Roche AG (CH) 2012-09-19 EP disclosed
WO-2011057973-A1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 WO disclosed